Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAFG | O15525 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 3/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.51 |
| ▸ | KRAS | P01116 | 6/20 | 0.50 |
| ▸ | PRKAR2A | P13861 | 2/20 | 0.49 |
| ▸ | PRKAR2B | P31323 | 2/20 | 0.49 |
| ▸ | RXFP3 | Q9NSD7 | 5/20 | 0.48 |
| ▸ | RXFP4 | Q8TDU9 | 4/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17880429 | 0.69 | MDM2 (0.71) | ESR1ESR2 | |
| SCHEMBL29637723 | 0.66 | PRKAR2A (0.94) | ESR1ESR2PRKAR2APRKAR2B | |
| SCHEMBL22802821 | 0.66 | ESR1 (0.49) | ESR1ESR2PRKAR2APRKAR2BRXFP3 | |
| SCHEMBL24918858 | 0.66 | KRAS (0.52) | MAFGESR1ESR2KRAS | |
| SCHEMBL17568833 | 0.65 | ESR1 (0.62) | ESR1ESR2KRASNFE2L2 | |
| SCHEMBL24918853 | 0.65 | BCL2A1 (0.50) | MAFGESR1ESR2KRASNFE2L2 | |
| SCHEMBL17880430 | 0.65 | MDM2 (0.78) | ESR1KRAS | |
| SCHEMBL20694360 | 0.65 | ESR1 (0.49) | MAFGESR1ESR2KRASPRKAR2A | |
| SCHEMBL20694568 | 0.65 | ESR1 (0.44) | MAFGESR1ESR2KRASPRKAR2A | |
| SCHEMBL14947855 | 0.65 | MCL1 (0.47) | ESR1ESR2KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185821-A1 | Z-SELECTIVE OLEFIN METATHESIS OF PEPTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185821-A1 | Z-SELECTIVE OLEFIN METATHESIS OF PEPTIDES | QPCT, PTMS, MAX | MAFG 632/4885ESR1 3422/4885ESR2 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.